Urinary Incontinence Devices Market By Product Type (Catheters, Electrical Stimulation Devices, Urethral Slings, Artificial Urinary Sphincters, Absorbent and Penile Compression Products); By Gender (Female, Male); By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Homecare, Long-Term Care Facilities); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation, Forecast, 2026–2032

Urinary Incontinence Devices Market: Reimbursement, Treatment Conversion, and Portfolio Expansion Shape Revenue Growth

The Global Urinary Incontinence Devices Market was valued at USD 4.20 billion in 2025 and is projected to reach USD 6.90 billion by 2032, growing at a CAGR of 7.4%, according to Strategic Market Research.

 

Recent urinary incontinence device innovation is centered on less invasive neuromodulation and home-use stimulation technologies. FDA-approved options include Medtronic’s Altaviva, a tibial nerve implant placed near the ankle with an expected 15-year battery life, and BlueWind Medical’s Revi/Revi Extend, another long-life implantable tibial neuromodulation system for urgency urinary incontinence. Medtronic’s InterStim remains an established sacral neuromodulation platform that regulates bladder-control nerves. Non-invasive products such as Elitone and Elitone URGE use external neuromuscular stimulation to treat stress and urge incontinence without requiring a prescription. Conventional approaches, including pessaries and transurethral bulking agents, continue to support the treatment of stress urinary incontinence.

 

The pipeline includes Neuspera’s iSNM System, an ultra-small wireless sacral neuromodulation device designed to stimulate deep pelvic nerves for overactive bladder and urge incontinence. Future development is focused on smaller leadless implants, remote programming, longer-lasting rechargeable batteries, and technologies intended to reduce repeat procedures. Researchers are also studying closed-loop biomodulation systems that could automatically adjust stimulation based on changes in bladder pressure and filling.

 

Urinary Incontinence Devices Market Segment Analysis

The segment structure is estimated using epidemiology, procedure volumes, product utilization, reimbursement trends, and the approved global market totals. Catheters account for the largest revenue share, while electrical stimulation devices are expected to record the fastest growth during the forecast period.

Urinary Incontinence Devices Market by Product Type

Catheters are estimated to account for 34.0% of global revenue in 2025, equal to USD 1.428 billion. Segment revenue is projected to reach USD 2.381 billion by 2032, representing a CAGR of 7.6% and a forecast market share of 34.5%. Recurring use among patients with permanent incontinence, neurological dysfunction, limited mobility, and impaired bladder emptying gives catheters a larger commercial base than most one-time implants. External and intermittent catheters also benefit from home-delivery services and monthly replacement patterns. Urinary collection products and catheters are among the categories most closely linked with recurring supply demand.

Electrical stimulation devices are projected to record the highest product-type CAGR at 11.5%. Revenue is expected to increase from USD 588 million in 2025 to USD 1.263 billion by 2032. Market share rises from 14.0% to 18.3% during the forecast period. Low neuromodulation penetration among diagnosed urgency-incontinence patients leaves room for treatment conversion after medicines, bladder training, or botulinum toxin fail. Boston Scientific’s USD 3.7 billion Axonics acquisition, Medtronic’s FDA-approved Altaviva tibial neuromodulation system, and Neuspera’s externally powered sacral platform have expanded competition beyond conventional sacral implants. New power strategies and implant locations are widening the number of patients and physicians able to consider advanced stimulation therapy.

Urethral slings represent an estimated 18.0% of the market in 2025, equivalent to USD 756 million. Revenue is forecast to reach USD 1.152 billion by 2032 at a CAGR of 6.2%. Market share declines to 16.7% because catheters and neuromodulation are expanding faster. FDA evidence supporting comparable outcomes between mini-slings and traditional midurethral slings has reduced regulatory uncertainty. Caldera Medical’s acquisition of the Gynecare TVT family also protects the commercial value of established platforms by maintaining familiar manufacturing, materials, and clinical workflows.

Artificial urinary sphincters account for approximately 8.0% of 2025 revenue, or USD 336 million. Segment revenue is projected to reach USD 531 million by 2032 at a CAGR of 6.8%. The patient pool is smaller than the populations served by catheters or female stress-incontinence products, but each implant generates greater procedure value. Boston Scientific has reported cumulative sales of more than 250,000 AMS 800 artificial urinary sphincters. Growth remains constrained by reconstructive-urology capacity, radiation history, urethral condition, and revision risk.

Absorbent and penile compression products represent 26.0% of the market in 2025, equal to USD 1.092 billion. Revenue is forecast to reach USD 1.573 billion by 2032 at a CAGR of 5.4%. Market share falls to 22.8% as external collection, implantable treatment, and outpatient intervention gain adoption. Absorbent products retain broad accessibility, but mature product formats face greater price competition and weaker differentiation than proprietary collection systems or implants.

 

Urinary Incontinence Devices Market by Gender

Female patients account for an estimated 68.0% of global market revenue in 2025, equivalent to USD 2.856 billion. Revenue is projected to reach USD 4.589 billion by 2032 at a CAGR of 7.0%, giving women a forecast market share of 66.5%. Higher prevalence and a wider treatment pathway support female revenue across slings, bulking systems, pessaries, pelvic-floor devices, catheters, external collection systems, and absorbent products.

Male patients represent 32.0% of 2025 revenue, or USD 1.344 billion. The segment is projected to grow at 8.1% annually and reach USD 2.311 billion by 2032. Its market share rises to 33.5%. Male growth benefits from two commercially distinct pathways. Artificial urinary sphincters and male slings preserve high procedure value among patients with persistent post-prostate-treatment leakage. External catheters, compression products, and collection systems produce recurring revenue among patients who remain unsuitable for surgery or prefer non-invasive management.

 

Urinary Incontinence Devices Market by End User

Hospitals and clinics account for 41.0% of market revenue in 2025, equal to USD 1.722 billion. Revenue is forecast to reach USD 2.657 billion by 2032 at a CAGR of 6.4%. Market share falls to 38.5% as procedures and long-term management shift toward ambulatory and home settings. Hospitals retain their leading position because diagnosis, specialist consultation, artificial-sphincter implantation, sling surgery, and complex neurological cases remain concentrated in hospital-based urology and urogynecology departments.

Ambulatory surgical centers represent 19.0% of 2025 revenue, or USD 798 million. The segment is expected to record the highest end-user CAGR at 8.9%, reaching USD 1.449 billion by 2032. Market share rises to 21.0%. Sling procedures, urethral bulking, neuromodulation trials, and selected permanent implants can be performed in outpatient settings. Payers and providers can lower facility costs and preserve hospital capacity by shifting suitable cases toward ASCs. Device companies that simplify inventory, reimbursement, and clinician training are positioned to gain faster access to this channel.

Homecare accounts for an estimated 28.0% of 2025 revenue, equal to USD 1.176 billion. Revenue is projected to reach USD 2.035 billion by 2032 at an 8.2% CAGR, lifting market share to 29.5%. External catheters, intermittent catheters, collection devices, replacement bags, and absorbent products create repeat purchasing relationships outside hospitals. BD’s portable PureWick system extends external collection beyond bedside use, while Convatec’s home-service model links patient enrollment with recurring catheter fulfillment.

Long-term care facilities account for 12.0% of revenue in 2025, or USD 504 million. The segment is forecast to reach USD 759 million by 2032 at a CAGR of 6.0%. Market share falls to 11.0%. Frailty, limited mobility, cognitive impairment, and neurological disease support stable demand, but institutional contracts and reimbursement ceilings place greater pressure on unit pricing.

 

Urinary Incontinence Devices Market by Geography

North America represents 43.0% of global revenue in 2025, equivalent to USD 1.806 billion. Regional revenue is projected to reach USD 2.795 billion by 2032 at a CAGR of 6.4%. Market share declines to 40.5% as Asia Pacific expands more quickly. Medicare coverage, specialist urology capacity, home-delivery services, and early commercialization of neuromodulation systems support North American leadership.

Europe accounts for an estimated 29.0% of 2025 revenue, or USD 1.218 billion. Revenue is forecast to reach USD 1.897 billion by 2032 at a CAGR of 6.5%. Market share declines to 27.5%. Established catheter use, public reimbursement, and the regional presence of Convatec, Coloplast, Medtronic, and Laborie support a mature continence-care market. Growth will come mainly from replacement demand, ageing-related care, and wider advanced-therapy use.

Asia Pacific is projected to record the highest regional CAGR at 10.2%. Revenue is expected to rise from USD 840 million in 2025 to USD 1.656 billion by 2032, increasing market share from 20.0% to 24.0%. The region begins from a lower base of specialist procedures, organized homecare, and reimbursed continence products. Expanding private hospitals, urology services, ambulatory care, and medical-supply distribution provide more room for patient conversion than mature Western markets.

Latin America represents 5.0% of global revenue in 2025, equal to USD 210 million. Revenue is projected to reach USD 359 million by 2032 at a CAGR of 8.0%. Growth will remain concentrated in private hospitals, urban urology centers, and distributor-led catheter channels.

The Middle East and Africa account for 3.0% of 2025 revenue, or USD 126 million. Revenue is projected to reach USD 193 million by 2032 at a CAGR of 6.3%. Demand remains concentrated in large hospitals, private healthcare networks, and recurring catheter supply. Limited specialist capacity and uneven reimbursement slow adoption of slings, artificial sphincters, and neuromodulation outside higher-income markets.

 

Underdiagnosis Limits the Conversion of Prevalence into Revenue

Approximately 91.55 million U.S. adults aged 20 or older may experience urinary-incontinence symptoms, based on NIDDK prevalence rates applied to the July 2025 population. The closest published global estimate identified 423 million adults with urinary incontinence in 2018. Claims activity is substantially smaller. In 2021, 1.48 million Medicare fee-for-service beneficiaries aged 65 or older had a urinary-incontinence diagnosis, including 1.06 million women and 428,214 men.

Patient reluctance to report leakage suppresses specialist referrals and delays device use. Fewer than 40% of adults who self-report incontinence tell a physician, according to the NIDDK evidence included in the supplied research. Patients who remain outside formal care usually rely on absorbent products or change daily activities. Manufacturers of slings, neuromodulation systems, sphincters, and reimbursed collection products cannot access that population until diagnosis, referral, and coverage occur.

Suppliers with physician education, patient-identification programs, prior-authorization support, and home-delivery enrollment can improve treatment conversion. Product performance alone does not overcome low diagnosis rates or incomplete reimbursement documentation.

 

Reimbursement and Service Infrastructure Determine Recurring Revenue

Convatec’s Continence Care revenue reached USD 537 million in 2025 and increased 6.6% organically. U.S. patient-volume growth, customer service, and GentleCath sales supported the result. Convatec-manufactured products represented about 59% of category revenue, giving the company greater control over margins and reducing dependence on third-party products.

BD recorded repeated double-digit PureWick growth across fiscal 2025 and the first half of fiscal 2026. Growth across several reporting periods indicates sustained adoption of male and female external-catheter systems rather than a short launch effect.

CMS policy creates a defined reimbursement route but limits excessive utilization. The April 2026 Urological Supplies policy added the Tibbe female external urinary device under HCPCS code A4318 and generally permits one unit per day. Suppliers must also maintain written orders, medical-necessity records, proof of delivery, and refill documentation.

 

Neuromodulation Is Expanding Beyond Conventional Sacral Systems

NIDDK identified 392,735 Medicare fee-for-service patients aged 65 or older with urgency urinary incontinence in 2021. Approximately 3.2% received a neuromodulation procedure, equal to about 12,568 patients or procedure events. The medically managed population was substantially larger. Approximately 99,154 patients filled an antimuscarinic prescription, 49,577 filled a beta-3 agonist prescription, and about 9,818 received botulinum toxin treatment or an associated procedure.

Boston Scientific entered sacral neuromodulation at scale through the Axonics acquisition. Boston Scientific’s Urology revenue increased 23.1% to USD 2.71 billion in 2025, while organic growth reached only 4.7%. Acquisitions contributed 17.9 percentage points, confirming that Axonics generated most of the reported increase.

Medtronic expanded the category through the FDA-approved Altaviva implantable tibial neuromodulation system. Neuspera introduced an externally powered sacral neuromodulation model with less implanted hardware. Hospitals and payers will compare these systems through procedure time, trial conversion, follow-up workload, replacement exposure, and lifetime treatment cost rather than purchase price alone.

 

External Collection Is Moving Beyond Bedside Care

BD launched the battery-powered PureWick Portable Collection System in November 2025 for wheelchair users requiring urine management outside bedside settings. More than 55 million PureWick external catheters had been sold by launch, and over 4,500 U.S. hospitals and rehabilitation facilities were using the technology.

Portable collection expands the number of settings in which the same patient can use compatible disposables. Bedside, wheelchair, rehabilitation, and home use can therefore feed one recurring product stream.

Convatec’s USD 537 million Continence Care business confirms that recurring supply growth depends on customer service, direct patient relationships, proprietary catheter mix, and fulfillment reliability. BD and Convatec are protecting revenue through installed systems and patient-service networks rather than competing only on unit price.

 

Competitive Positioning and Forecast Interpretation

Boston Scientific and Medtronic are competing through broad advanced-therapy portfolios. BD and Convatec rely more heavily on recurring supplies, proprietary consumables, and home-service reach. Caldera Medical, Coloplast, and Laborie hold more focused positions in slings, bulking, and pelvic-health procedures.

The projected increase from USD 4.2 billion in 2025 to USD 6.9 billion by 2032 is supported by three measurable shifts. Neuromodulation is expanding through acquisitions and new implant designs. Female stress-incontinence portfolios are consolidating around established surgical and bulking platforms. External collection is moving into portable and home-based use while reimbursement coding becomes more specific.

Pricing power will remain strongest where a product lowers lifetime treatment burden, protects clinical workflow, or creates proprietary recurring consumption. Mature catheters without differentiated services will face tighter reimbursement and supplier competition. Implant manufacturers will defend pricing through clinical evidence, physician training, and lower revision exposure.

Companies that connect diagnosis, reimbursement, treatment delivery, and post-procedure revenue will capture the largest share of the forecast USD 2.7 billion increase. Durable growth will come from portfolios that retain patients through consumables, programming, repeat injections, home services, revisions, and replacements.

 

Urinary Incontinence Devices Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.20 Billion
Revenue Forecast in 2032	USD 6.90 Billion
Overall Growth Rate	CAGR of 7.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Gender, By End User, By Geography
By Product Type	Catheters, Electrical Stimulation Devices, Urethral Slings, Artificial Urinary Sphincters, Absorbent and Penile Compression Products
By Gender	Female, Male
By End User	Hospitals and Clinics, Ambulatory Surgical Centers, Homecare, Long-Term Care Facilities
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Expansion of reimbursement coverage and home-delivery infrastructure, rising treatment conversion after medication failure, growing adoption of neuromodulation systems, increasing use of portable external urine-collection technologies
Customization Option	Available upon request